Poland· PL-100130202
Phenazolinum
A antazoline product containing antazolini mesilas, registered in Poland by Zakłady Farmaceutyczne POLPHARMA S.A..
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Antazolini mesilas
- Manufacturer
- Zakłady Farmaceutyczne POLPHARMA S.A.
- Country
- Poland (PL)
- ATC code
- R06AX05
- ATC class
- Antazoline
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909990093410
- gtin05909990093427
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Antazoline in 1 other country
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c1a7c2fc-d316-4219-88df-5c940ca079c0 GET /v1/drugs/c1a7c2fc-d316-4219-88df-5c940ca079c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "50 mg/ml",
"packaging": "05909990093410 ¦ Rp ¦ 7940\n10 amp. 2 ml\n05909990093427 ¦ Rp ¦ Skasowane ¦ 7941\n50 amp. 2 ml",
"substance": "Antazolini mesilas 50 mg",
"common_name": "Antazolini mesilas",
"pl_product_id": "100130202",
"pozwolenie_nr": "00934",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about antazoline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.